Angiotensin II receptor one (AT1) mediates dextrose induced endoplasmic reticulum stress and superoxide production in human coronary artery endothelial cells

International Journal of Cardiology

Volumn 220, Issue , 2016, Pages 842-850

  Haas, Michael J ^a   Onstead Haas, Luisa ^a   Lee, Tracey ^a   Torfah, Maisoon ^a   Mooradian, Arshag D ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; Endoplasmic reticulum stress; Endothelial cells; Hyperglycemia; Oxidative stress; Renin angiotensin system

Indexed keywords

2 METHYL 6 (4 METHOXYPHENYL) 3,7 DIHYDROIMIDAZO[1,2 A]PYRAZIN 3 ONE; ALKALINE PHOSPHATASE; ANGIOTENSIN RECEPTOR; AT1 PROTEIN; CANDESARTAN; CAPTOPRIL; EUKARYOTIC TRANSLATION INITIATION FACTOR 2ALPHA; GLUCOSE; GLUCOSE REGULATED PROTEIN 78; INITIATION FACTOR; LISINOPRIL; LOSARTAN; PHENAZONE; SPIRONOLACTONE; STRESS ACTIVATED PROTEIN KINASE 1; SUPEROXIDE; UNCLASSIFIED DRUG; AGTRAP PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ARTICLE; CHEMOLUMINESCENCE; CONTROLLED STUDY; CORONARY ARTERY; ENDOPLASMIC RETICULUM STRESS; ENDOTHELIUM CELL; ENZYME ASSAY; GENE SILENCING; HUMAN; HUMAN CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RECEPTOR BLOCKING; WESTERN BLOTTING; CELL SURVIVAL; CORONARY BLOOD VESSEL; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; PHYSIOLOGY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CELL SURVIVAL; CORONARY VESSELS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOPLASMIC RETICULUM STRESS; ENDOTHELIAL CELLS; GLUCOSE; HUMANS; SUPEROXIDES;

EID: 84978829955     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.06.094     Document Type: Article

References (37)

1. [1] Bender, S.B., Jia, G., Sowers, J.R., Mineralocorticoid receptors: an appealing target to treat coronary microvascular dysfunction in diabetes. Diabetes 64 (2015), 3–5.
2. [2] Garg, R., Rao, A.D., Baimas-George, M., et al. Mineralocorticoid receptor blockade improves coronary microvascular function in individuals with type 2 diabetes. Diabetes 64 (2015), 236–242.
3. [3] Al Chekakie, M.O., Traditional heart failure medications and sudden cardiac death prevention: a review. J. Cardiovasc. Pharmacol. Ther. 18 (2012), 412–426.
4. [4] Yusuf, S., Two decades of progress in preventing vascular disease. Lancet 360 (2002), 2–3.
5. [5] Lakshmanan, A.P., Thandavarayan, R.A., Palaniyandi, S.S., et al. Modulation of AT-1R/CHOP-JNK-Caspase12 pathway by olmesartan treatment attenuates ER stress-induced renal apoptosis in streptozotocin-induced diabetic mice. Eur. J. Pharm. Sci. 44 (2011), 627–634.
6. [6] Sun, H.L., Sun, L., Li, Y.Y., Shao, M.M., Cheng, X.Y., Ge, N., Lu, J.D., Li, S.M., ACE inhibitor suppresses the apoptosis induced by endoplasmic reticulum stress in renal tubular in experimental diabetic rats. Exp. Clin. Endocrinol. Diabetes 117 (2009), 336–344.
7. [7] Wu, T., Dong, Z., Geng, J., Sun, Y., Liu, G., Kang, W., Zhang, Y., Ge, Z., Valsartan protects against ER stress-induced myocardial apoptosis via CHOP/Puma signaling pathway in streptozotocin-induced diabetic rats. Eur. J. Pharm. Sci. 42 (2011), 496–502.
8. [8] Privratsky, J.R., Wold, L.E., Sowers, J.R., Quinn, M.T., Ren, J., AT1 blockade prevents glucose-induced cardiac dysfunction in ventricular myocytes role of the AT1 receptor and NADPH oxidase. Hypertension 42 (2003), 206–212.
9. [9] Nickenig, G., Harrison, D.G., The AT1-type angiotensin receptor in oxidative stress and atherogenesis, part I: oxidative stress and atherogenesis. Circulation 105 (2002), 393–396.
10. [10] Sowers, J.R., Hypertension, angiotensin II, and oxidative stress. N. Engl. J. Med. 346 (2002), 1999–2001.
11. [11] Wong, W.T., Tian, X.Y., Xu, A., Ng, C.F., Lee, H.K., Chen, Z.Y., Au, C.L., Yao, X., Huang, Y., Angiotensin II type 1 receptor-dependent oxidative stress mediates endothelial dysfunction in type 2 diabetic mice. Antioxid. Redox Signal. 13 (2010), 757–768.
12. [12] Nguyen Dinh Cat, A., Montezano, A.C., Burger, D., Touyz, R.M., Angiotensin II, NADPH oxidase, and redox signaling in the vasculature. Antioxid. Redox Signal. 19 (2013), 1110–1120.
13. [13] Leehey, D.J., Isreb, M.A., Marcic, S., Singh, A.K., Singh, R., Effect of high glucose on superoxide in human mesangial cells: role of angiotensin II. Nephron Exp. Nephrol. 100 (2005), e46–e53.
14. [14] Zhang, H., Schmeisser, A., Garlichs, C.D., Plötze, K., Damme, U., Mügge, A., Daniel, W.G., Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: role of membrane-bound NADH-/NADPH-oxidases. Cardiovasc. Res. 44 (1999), 215–222.
15. [15] Chambers, J.E., Marciniak, S.J., Cellular mechanisms of endoplasmic reticulum stress signaling in health and disease. 2. Protein misfolding and ER stress. Am. J. Physiol. Cell Physiol. 307 (2014), C657–C670.
16. [16] Sheikh-Ali, M., Sultan, S., Alamir, A., Haas, M.J., Mooradian, A.D., Hyperglycemia-induced endoplasmic reticulum stress in endothelial cells. Nutrition 26 (2010), 1146–1150.
17. [17] Sheikh-Ali, M., Sultan, S., Alamir, A., Haas, M.J., Mooradian, A.D., Effects of antioxidants on glucose-induced oxidative stress and endoplasmic reticulum stress in endothelial cells. Diabetes Res. Clin. Pract. 87 (2010), 161–166.
18. [18] Hiramatsu, N., Kasai, A., Hayakawa, K., Yao, J., Kitamura, M., Real-time detection and continuous monitoring of ER stress in vitro and in vivo by ES-TRAP: evidence for systemic, transient ER stress during endotoxemia. Nucleic Acids Res., 34, 2006, e93.
19. [19] Decker, T., Lohmann-Matthes, M.L., A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J. Immunol. Methods 115 (1988), 61–69.
20. [20] Haas, M.J., Kurban, W., Shah, H., Onstead-Haas, L., Mooradian, A.D., Beta blockers suppress dextrose-induced endoplasmic reticulum stress, oxidative stress, and apoptosis in human coronary artery endothelial cells. Am. J. Ther., 27, Jan 2015 (Epub ahead of print).
21. [21] Kojanian, H., Szafran-Swietlik, A., Onstead-Haas, L.M., Haas, M.J., Mooradian, A.D., Statins prevent dextrose-induced endoplasmic reticulum stress and oxidative stress in endothelial and HepG2 cells. Am. J. Ther., 5, May 2014 (Epub ahead of print).
22. [22] Goeke, N.M., Olson, B.J., Klenk, D.C., Measurement of protein using bicinchoninic acid. Anal. Biochem. 150 (1985), 76–85.
23. [23] Laemmli, U.K., Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970), 680–685.
24. [24] Towbin, H., Staehelin, T., Gordon, J., Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets. Proc. Natl. Acad. Sci. U. S. A. 76 (1979), 4350–4354.
25. [25] Oberleithner, H., Ludwig, T., Riethmu¨ller, C., Hillebrand, U., Albermann, L., Scha¨fer, C., Shahin, V., Schillers, H., Human endothelium: target for aldosterone. Hypertension 43 (2004), 952–956.
26. [26] Peng, H., Xing, Y.F., Ye, Z.C., Li, C.M., Luo, P.L., Li, M., Lou, T.Q., High glucose induces activation of the local renin–angiotensin system in glomerular endothelial cells. Mol. Med. Rep. 9 (2014), 450–456.
27. [27] Tang, S.S., Stevenson, L., Dzau, V.J., Endothelial renin–angiotensin pathway. Adrenergic regulation of angiotensin secretion. Circ. Res. 66 (1990), 103–108.
28. [28] Dagenais, G.R., Pogue, J., Fox, K., Simoons, M.L., Yusuf, S., Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 368 (2006), 581–588.
29. [29] Reboldi, G., Angeli, F., Cavallini, C., Gentile, G., Mancia, G., Verdecchia, P., Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. J. Hypertens. 26 (2008), 1282–1289.
30. [30] Bavry, A.A., Handberg, E.M., Huo, T., et al. Aldosterone inhibition and coronary endothelial function in women without obstructive coronary artery disease: an ancillary study of the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation. Am. Heart J. 167 (2014), 826–832.
31. [31] Kawata, T., Daimon, M., Hasegawa, R., et al. Effect on coronary flow velocity reserve in patients with type 2 diabetes mellitus: comparison between angiotensin-converting enzyme inhibitor and angiotensin II type 1 receptor antagonist. Am. Heart J., 151, 2006, 798, e92e15.
32. [32] Kjaer, A., Kristoffersen, U.S., Tarnow, L., Parving, H.-H., Hesse, B., Short-term oral treatment with the angiotensin II receptor antagonist losartan does not improve coronary vasomotor function in asymptomatic type 2 diabetes patients. Diabetes Res. Clin. Pract. 84 (2009), 34–38.
33. [33] Zheng, Z., Chen, H., Ke, G., Fan, Y., Zou, H., Sun, X., Gu, Q., Xun Xu, X., Ho, P.C.P., Protective effect of perindopril on diabetic retinopathy is associated with decreased vascular endothelial growth factor-to-pigment epithelium-derived factor ratio. Involvement of a mitochondria-reactive oxygen species pathway. Diabetes 58 (2009), 954–964.
34. [34] Scribner, A.W., Loscalzo, J., Napoli, C., The effect of angiotensin-converting enzyme inhibition on endothelial function and oxidant stress. Eur. J. Pharmacol. 482 (2003), 95–99.
35. [35] Mooradian, A.D., Haas, M.J., Glucose-induced endoplasmic reticulum stress is independent of oxidative stress: a mechanistic explanation for the failure of antioxidant therapy in diabetes. Free Radic. Biol. Med. 50 (2011), 1140–1143.
36. [36] Mooradian, A.D., Onstead-Haas, L., Haas, M.J., Asymmetrical cross-talk between the endoplasmic reticulum stress and oxidative stress caused by dextrose. Life Sci. 144 (2016), 37–48.
37. [37] Corkey, R.F., Corkey, B.E., Gimbrone, M.A. Jr., Hexose transport in normal and SV40-transformed human endothelial cells in culture. J. Cell. Physiol. 106 (1981), 425–434.